[{"address1": "11250 El Camino Real", "address2": "Suite 100", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 410 0266", "website": "https://skyebioscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension. It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.", "fullTimeEmployees": 11, "maxAge": 86400, "priceHint": 2, "previousClose": 8.93, "open": 8.99, "dayLow": 7.295, "dayHigh": 8.99, "regularMarketPreviousClose": 8.93, "regularMarketOpen": 8.99, "regularMarketDayLow": 7.295, "regularMarketDayHigh": 8.99, "beta": 1.633, "forwardPE": -7.330189, "volume": 1096091, "regularMarketVolume": 1096091, "averageVolume": 117841, "averageVolume10days": 457480, "averageDailyVolume10Day": 457480, "bid": 7.64, "ask": 7.9, "bidSize": 100, "askSize": 200, "marketCap": 218087584, "fiftyTwoWeekLow": 1.44, "fiftyTwoWeekHigh": 19.41, "fiftyDayAverage": 12.2678, "twoHundredDayAverage": 6.938035, "currency": "USD", "enterpriseValue": 139457376, "floatShares": 11672881, "sharesOutstanding": 28067900, "sharesShort": 232398, "sharesShortPriorMonth": 46740, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0083, "heldPercentInsiders": 0.07083, "heldPercentInstitutions": 0.57811, "shortRatio": 3.33, "shortPercentOfFloat": 0.013200001, "impliedSharesOutstanding": 28067900, "bookValue": 2.811, "priceToBook": 2.7641408, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -37496796, "trailingEps": -4.18, "forwardEps": -1.06, "lastSplitFactor": "1:250", "lastSplitDate": 1694131200, "enterpriseToEbitda": -8.476, "52WeekChange": 0.29499996, "SandP52WeekChange": 0.26238096, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "SKYE", "underlyingSymbol": "SKYE", "shortName": "Skye Bioscience, Inc.", "longName": "Skye Bioscience, Inc.", "firstTradeDateEpochUtc": 1420554600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f0ec0a4d-b670-3424-93a4-f9095a3b0984", "messageBoardId": "finmb_266974060", "gmtOffSetMilliseconds": -14400000, "currentPrice": 7.77, "targetHighPrice": 21.0, "targetLowPrice": 14.0, "targetMeanPrice": 18.33, "targetMedianPrice": 20.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 83465960, "totalCashPerShare": 2.974, "ebitda": -16453414, "totalDebt": 4835691, "quickRatio": 5.317, "currentRatio": 5.985, "debtToEquity": 6.13, "returnOnAssets": -0.20834999, "returnOnEquity": -1.01202, "freeCashflow": -14795656, "operatingCashflow": -14599378, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]